<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036790</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069322</org_study_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>WCCC-CO-01910</secondary_id>
    <secondary_id>PCI-PCYC-0207</secondary_id>
    <secondary_id>NCI-G02-2061</secondary_id>
    <nct_id>NCT00036790</nct_id>
  </id_info>
  <brief_title>Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer</brief_title>
  <official_title>An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin&#xD;
      by making tumor cells more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with&#xD;
      doxorubicin in treating patients who have recurrent or metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of motexafin gadolinium and doxorubicin in patients&#xD;
           with advanced malignancies.&#xD;
&#xD;
        -  Determine the dose-limiting toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Evaluate the tumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are assigned to 1 of 2&#xD;
      groups.&#xD;
&#xD;
      Group A:&#xD;
&#xD;
        -  Course 1: Patients receive motexafin gadolinium IV over 30 minutes on days 1, 8, 9, and&#xD;
           10 and doxorubicin IV over 15 minutes on day 8.&#xD;
&#xD;
        -  Course 2: 28 days after the beginning of course 1, patients receive doxorubicin IV over&#xD;
           15 minutes.&#xD;
&#xD;
        -  Courses 3-6: Beginning 21 days after course 2, patients receive doxorubicin IV over 15&#xD;
           minutes on day 1 and motexafin gadolinium IV over 30 minutes on days 1-3. Treatment&#xD;
           repeats every 21 days.&#xD;
&#xD;
      Group B:&#xD;
&#xD;
        -  Course 1: Patients receive motexafin gadolinium IV over 30 minutes on day 1 and&#xD;
           doxorubicin IV over 15 minutes on day 8.&#xD;
&#xD;
        -  Course 2: 28 days after the beginning of course 1, patients receive doxorubicin IV over&#xD;
           15 minutes on day 1 and motexafin gadolinium IV over 30 minutes on days 1-3.&#xD;
&#xD;
        -  Courses 3-6: Beginning 21 days after course 2, patients receive doxorubicin and&#xD;
           motexafin gadolinium as in group A.&#xD;
&#xD;
      Treatment in both groups continues for up to 6 courses in the absence of disease progression,&#xD;
      unacceptable toxicity, or a cumulative doxorubicin dose of 450 mg/m^2.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of doxorubicin and motexafin gadolinium&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose&#xD;
      at which no more than 0 of 3 or 1 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 1 and 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-48 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lung Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Prostate Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>motexafin gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced malignancy that is considered incurable&#xD;
&#xD;
               -  Recurrent or metastatic disease&#xD;
&#xD;
               -  Relapsed solid tumors include, but are not limited to the following sites:&#xD;
&#xD;
                    -  Lung&#xD;
&#xD;
                    -  Breast&#xD;
&#xD;
                    -  Colon&#xD;
&#xD;
                    -  Prostate&#xD;
&#xD;
                    -  Head and neck&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF greater than 45% at rest&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No clinically significant ventricular arrhythmias&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of HIV infection&#xD;
&#xD;
          -  No history of porphyria&#xD;
&#xD;
          -  No glucose-6-phosphate dehydrogenase deficiency&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy&#xD;
&#xD;
          -  No prior lifetime cumulative doxorubicin exposure of more than 300 mg/m^2&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 14 days since prior multidrug resistance-modulating drugs (e.g., PSC833 or&#xD;
             cyclosporine)&#xD;
&#xD;
          -  No other concurrent antineoplastic or investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Renschler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>limited stage small cell lung cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent lip and oral cavity cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage IV lip and oral cavity cancer</keyword>
  <keyword>recurrent paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage IV paranasal sinus and nasal cavity cancer</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent hypopharyngeal cancer</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage IV hypopharyngeal cancer</keyword>
  <keyword>recurrent laryngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage IV laryngeal cancer</keyword>
  <keyword>recurrent oropharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage IV oropharyngeal cancer</keyword>
  <keyword>recurrent nasopharyngeal cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

